Posted by Michael Wonder on 14 Mar 2024
Exagamglogene autotemcel for the treatment of patients with sickle cell disease
14 March 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the use of exagamglogene autotemcel in the NHS in England.
Foe the time being, exagamglogene autotemcel is not recommended for the treatment of patients 12 years and over with sickle cell disease with recurrent vaso-occlusive crises who have a β S/βS, βS/β+ or βS/β0 genotype, when haematopoietic stem cell transplantation is suitable and a human leukocyte antigen-matched related haematopoietic stem cell donor is not available.
